Designed endocytosis-inducing proteins degrade targets and amplify signals

Buwei Huang(University of Washington), Mohamad H. Abedi(University of Washington), Green Ahn(Stanford University), Brian Coventry(Howard Hughes Medical Institute), Isaac Sappington(University of Washington), Cong Tang(University of Lisbon), Rong Wang(The University of Texas Southwestern Medical Center), Thomas Schlichthaerle(University of Washington), Jason Z. Zhang(University of Washington), Yujia Wang(University of Washington), Inna Goreshnik(Howard Hughes Medical Institute), Ching Wen Chiu(University of Washington), Adam Chazin-Gray(University of Washington), Sidney Chan(University of Washington), Stacey Gerben(University of Washington), Analisa Murray(University of Washington), Shunzhi Wang(University of Washington), Jason O’Neill(Novo Nordisk (Denmark)), Yi Li(Novo Nordisk (Denmark)), Ronald Yeh(Novo Nordisk (Denmark)), Ayesha Misquith(Novo Nordisk (Denmark)), Anitra C. Wolf(Novo Nordisk (Denmark)), Luke M. Tomasovic(Johns Hopkins University), Dan I. Piraner(University of California, San Francisco), Maria J Duran Gonzalez(University of California, San Francisco), Nathaniel R. Bennett(University of Washington), Preetham Venkatesh(University of Washington), Maggie Ahlrichs(University of Washington), Craig L. Dobbins(University of Washington), Wei Yang(University of Washington), Xinru Wang(University of Washington), Danny D. Sahtoe(Hubrecht Institute for Developmental Biology and Stem Cell Research), Dionne Vafeados(University of Washington), Rubul Mout(Harvard University), Shirin Shivaei(California Institute of Technology), Longxing Cao(Westlake University), Lauren Carter(University of Washington), Lance Stewart(University of Washington), Jamie B. Spangler(Novo Nordisk (Denmark)), Kole T. Roybal(University of California, San Francisco), Per Greisen(Novo Nordisk (Denmark)), Xiaochun Li(The University of Texas Southwestern Medical Center), Gonçalo J. L. Bernardes(University of Lisbon), Carolyn R. Bertozzi(Howard Hughes Medical Institute), David Baker(Howard Hughes Medical Institute)
Nature
September 25, 2024
Cited by 116Open Access
Full Text

Abstract

Endocytosis and lysosomal trafficking of cell surface receptors can be triggered by endogenous ligands. Therapeutic approaches such as lysosome-targeting chimaeras1,2 (LYTACs) and cytokine receptor-targeting chimeras3 (KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target protein binders leads to lysosomal trafficking and target degradation. As these receptors have different tissue distributions, the different EndoTags could enable targeting of degradation to different tissues. EndoTag fusion to a PD-L1 antibody considerably increases efficacy in a mouse tumour model compared to antibody alone. The modularity and genetic encodability of EndoTags enables AND gate control for higher-specificity targeted degradation, and the localized secretion of degraders from engineered cells. By promoting endocytosis, EndoTag fusion increases signalling through an engineered ligand–receptor system by nearly 100-fold. EndoTags have considerable therapeutic potential as targeted degradation inducers, signalling activators for endocytosis-dependent pathways, and cellular uptake inducers for targeted antibody–drug and antibody–RNA conjugates. Computationally designed genetically encoded proteins can be used to target surface proteins, thereby triggering endocytosis and subsequent intracellular degradation, activating signalling or increasing cellular uptake in specific tissues.


Related Papers